Note J - Equity-based Compensation - Stock Options, SARs and RSUs Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Sep. 30, 2019		Jun. 30, 2019
Outstanding (in shares)		1,951
Outstanding, weighted average exercise price (in dollars per share)		$ 3.64
Outstanding, weighted average remaining contractual term (Year)	[1]	4 years 73 days	[2]	4 years 149 days
Outstanding, aggregate value		$ 18,979	[2],[3]
Options / SARs / RSUs cancelled/forfeited/expired (in shares)		(16)
Options / SARs / RSUs cancelled/forfeited/expired, weighted average exercise price (in dollars per share)		$ 1.11
Options / SARs exercised and RSUs vested (in shares)		(100)
Options / SARs exercised and RSUs vested, weighted average exercise price (in dollars per share)		$ 2.15
Outstanding (in shares)		1,835	[2]	1,951
Outstanding, weighted average exercise price (in dollars per share)		$ 3.75	[2]	$ 3.64
Exercisable (in shares)	[4]	617
Exercisable, weighted average exercise price (in dollars per share)	[4]	$ 9.63
Exercisable, weighted average remaining contractual term (Year)	[1],[4]	4 years 43 days
Exercisable, aggregate value	[3],[4]	$ 2,750
Stock Appreciation Rights (SARs) [Member]
Options granted (in shares)
Options granted (in dollars per share)
Non-option instruments granted (in shares)
Non-option instruments, weighted average exercise price (in dollars per share)
Restricted Stock Units (RSUs) [Member]
Non-option instruments granted (in shares)
Non-option instruments, weighted average exercise price (in dollars per share)

[1] Calculation of weighted average remaining contractual term does not include RSUs that were granted, which have indefinite contractual term.

[2] Due to the ceiling imposed on the SAR grants, the outstanding amount above can be exercised for a maximum of 1,762,694 shares of the Company's common stock as of September 30, 2019. SAR grants made on or after January 1, 2012 are convertible for a maximum number of shares of the Company's common stock equal to 50% of the SARs subject to the grant.

[3] Calculation of aggregate intrinsic value is based on the share price of the Company's common stock on September 30, 2019 ($14.09 per share).

[4] Due to the ceiling imposed on the SAR grants, the exercisable amount above can be exercised for a maximum of 577,014 shares of the Company's common stock as of September 30, 2019.